KCM
EWTX icon

Kennedy Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Kennedy Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Sell
256,608
-7,596
-3% -$262K 0.18% 188
2026
Q1 		$8.32M Buy
264,204
+22,695
+9% +$654K 0.18% 199
2025
Q4 		$5.99M Sell
241,509
-9,113
-4% -$183K 0.13% 265
2025
Q3 		$4.07M Sell
250,622
-1,902
-0.8% -$27K 0.09% 327
2025
Q2 		$3.31M Buy
252,524
+27,824
+12% +$401K 0.08% 356
2025
Q1 		$4.94M Sell
224,700
-11,942
-5% -$313K 0.12% 288
2024
Q4 		$6.32M Buy
236,642
+9,619
+4% +$306K 0.14% 262
2024
Q3 		$6.06M Sell
227,023
-45,048
-17% -$896K 0.13% 265
2024
Q2 		$4.9M Sell
272,071
-21,194
-7% -$370K 0.1% 322
2024
Q1 		$5.35M Sell
293,265
-49,599
-14% -$788K 0.11% 309
2023
Q4 		$3.75M Buy
+342,864
New +$2.41M 0.08% 361

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Kennedy Capital Management's EWTX Position: Q2 2026 in Review

Kennedy Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 2.9% in Q2 2026, selling an estimated $262K and leaving 256,608 shares worth $10.4M. The position accounts for 0.18% of the portfolio, ranked #188.

Kennedy Capital Management first reported a position in EWTX in Q4 2023 and has held it in 11 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Kennedy Capital Management held 256,608 shares of Edgewise Therapeutics worth $10.4M as of Q2 2026.
  • Kennedy Capital Management sold 7,596 Edgewise Therapeutics shares in Q2 2026, an estimated $262K.
  • Edgewise Therapeutics made up 0.18% of Kennedy Capital Management's portfolio in Q2 2026, its #188 holding.
  • Kennedy Capital Management first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.